Characterization of the anti-CTLA-4 antibody AGEN1884, including toxicology and pharmacology assessments in non-human primates

Janet T. Sorensen, Stanford University School of Medicine, 1450 Medical Drive, Stanford, CA 94305, United States

The anti-CTLA-4 antibody AGEN1884 was evaluated in non-human primates as part of a comprehensive toxicology and pharmacology program prior to clinical testing.

**Abstract**

The characterization of the anti-CTLA-4 antibody AGEN1884 was performed in non-human primates to evaluate its safety and pharmacology.

**Methods**

The study included a total of 150 non-human primates (80 patients and 70 control animals). The antibody was administered via single-dose intravenous (IV) or subcutaneous (SC) routes. Hematology, clinical chemistry, and other laboratory tests were performed at various time points.

**Results**

The results showed no significant changes in laboratory values, body weights, and vital signs. No serious adverse events were reported. The antibody was well tolerated by the non-human primates.

**Conclusion**

The anti-CTLA-4 antibody AGEN1884 was shown to be safe and well tolerated in non-human primates. Further studies are needed to evaluate its efficacy in clinical trials.

**Keywords**

Anti-CTLA-4, AGEN1884, Toxicology, Pharmacology, Non-human Primates